ESR1 and breast cancer: For example, NeoPalAna evaluated neoadjuvant palbociclib plus anastrozole for early ER+/HER2- breast cancer and showed that the addition of palbociclib enhanced anti-proliferation over and beyond endocrine therapy alone as evidenced by rates of CCCA30.